Graft-Versus-Host Disease

  • J. Jansen
  • Q. Chang
  • L. P. Akard
Part of the Developments in Hematology and Immunology book series (DIHI, volume 28)


The development of nuclear arms at the end of World War II was a major stimulus for research into radiation damage to the hematopoietic system and into the treatment of such damage through bone marrow transplantation [1]. A large body of research with mice, dogs, and monkeys established a “bone marrow syndrome” with death through the complications of pancytopenia after a total body dose of 5–7 Gy (500–700 rad). Such animals could be salvaged by the infusion of syngeneic bone marrow [2] or allogeneic bone marrow [3,4]. These studies were trailblazers for bone marrow transplantation as therapeutic modality in man.


Bone Marrow Transplantation Allogeneic Bone Marrow Allogeneic Bone Marrow Transplantation Marrow Graft Syngeneic Bone Marrow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Santos GW. History of bone marrow transplantation. Clin Haematol 1983;12:611–41.PubMedCrossRefGoogle Scholar
  2. 2.
    Lorenz E, Uphoff DE, Reid TR, Shelton E. Modification of acute irradiation injury in mice and guinea pigs by bone marrow infections. J Nat Cancer Inst 1951; 12:197–201.PubMedGoogle Scholar
  3. 3.
    Lorenz E, Congdon CC. Modification of lethal irradiation injury in mice by injection of homologous and heterologous bone marrow. J Nat Cancer Inst 1954;14:955–61.PubMedGoogle Scholar
  4. 4.
    Van Bekkum DW, de Vries MJ. Radiation chimaeras. Logos Press Limited, New York, 1967.Google Scholar
  5. 5.
    Barnes DWH, Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Brit J Haematol 1957;3:241–52.CrossRefGoogle Scholar
  6. 6.
    Billingham RE, Brent L. A simple method for inducing tolerance of skin homografts in mice. Transplantation Bulletin 1957;4:67–71.PubMedGoogle Scholar
  7. 7.
    Billingham RE. The biology of graft-versus-host reactions. Harvey Lectures 1966-67;62:21–78.PubMedGoogle Scholar
  8. 8.
    Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantations. N Engl J Med 1975;292:832–43, 895-902.PubMedCrossRefGoogle Scholar
  9. 9.
    Sale G. Shulman HM (eds). The pathology of bone marrow transplantation. Masson Publishing USA, Inc., Seattle, 1984.Google Scholar
  10. 10.
    Brubaker DB. Human posttransfusion graft-versus-host disease. Vox Sang 1983; 45:401–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Burdick JF, Vogelsang GB, Smith WJ, et al. Severe graft-versus-host disease in a liver-transplant recipient. Medical Intelligence 1988;318:689–91.Google Scholar
  12. 12.
    Deeg HJ, Storb R, Shulman H. Engraftment of DLA-nonidentical unrelated canine marrow graft after high-dose fractionated total body irradiation. Transplantation 1982;33:443–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Vogelsang GB, Wagner JE. Graft-versus-host disease. Hemat/Oncol Clin Nrth Amer 1990;4:625–39.Google Scholar
  14. 14.
    Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Brit J Haematol 1987;67:397–406.CrossRefGoogle Scholar
  15. 15.
    Neudorf S, Filipovich A, Ramsay N, Kersey K. Prevention and treatment of acute graft-versus-host disease. Sem Hematol 1984;21:91–100.Google Scholar
  16. 16.
    Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985;313:765–71.PubMedCrossRefGoogle Scholar
  17. 17.
    Ash RC, Casper JT, Chitambar CR, et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 1990;322:485–94.PubMedCrossRefGoogle Scholar
  18. 18.
    Starzl TE, Demetris AJ, van Thiel D. Liver transplantation. N Engl J Med 1989;321:1014–22,1092-9.PubMedCrossRefGoogle Scholar
  19. 19.
    Von Fliedner V, Higby DI, Kim U. Graft-versus-host reaction following blood product transfusion. Am J Med 1982;72:951–61.CrossRefGoogle Scholar
  20. 20.
    Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med 1990;323:315–21.PubMedCrossRefGoogle Scholar
  21. 21.
    Park BH, Good RA, Gate J, Burke B. Fatal graft-versus-host reaction following transfusion of allogeneic blood and plasma in infants with combined immunodeficiency disease. Transplant Proc 1974;6:385–7.PubMedGoogle Scholar
  22. 22.
    Parkman R, Mosier D, Umansky I, Cochran W, Carpenter CB, Rosen FS. Graft-versus-host disease after intrauterine and exchange transfusions for hemolytic disease of the newborn. N Eng J Med 1974;290:359–63.CrossRefGoogle Scholar
  23. 23.
    Dinsmore RE, Straus DJ, Pollack MS, et al. Fatal graft-versus-host disease following blood transfusion in Hodgkin’s disease documented by HLA typing. Blood 1980;55: 831–4.PubMedGoogle Scholar
  24. 24.
    Lowenthal RM, Grossman L, Goldman JM, et al. Granulocyte transfusions in treatment of infections in patients with acute leukemia and aplastic anaemia. Lancet 1975;i:353–8.CrossRefGoogle Scholar
  25. 25.
    Thaler M, Shamiss A, Orgad S, et al. The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery. N Engl J Med 1989;321:25–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Otsuka S, Kunieda K, Hirose M, et al. Fatal erythroderma (suspected graft-versus-host disease) after cholecystectomy: Retrospective analysis. Transfusion 1989;29: 544–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Holland PV. Prevention of transfusion-associated graft-versus-host disease. Arch Pathol Lab Med 1989;113:285–91.PubMedGoogle Scholar
  28. 28.
    Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells from fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981;ii:327-31.Google Scholar
  29. 29.
    De Witte T, Hoogenhout J, de Pauw B, et al. Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic bone marrow transplantation. Blood 1986;67:1302–8.PubMedGoogle Scholar
  30. 30.
    Ferrara J, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324:667–74.PubMedCrossRefGoogle Scholar
  31. 31.
    Korngold R, Sprent J. Lethal graft-versus-host disease across minor histocompatibility barriers in mice. In: Nathan DG (ed). Clinics in haematology 1983;681–93.Google Scholar
  32. 32.
    Unanue ER, Allen PM. The basis for the immunoregulatory role of macrophages and other accessory cells. Science 1987;236:551–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Samelson LE, Patel MD, Weissmann AM, Harford JB, Klausner RD. Antigen activation of murine T-cells induces tyrosine phosphorylation of a polypeptide associated with the T-cells antigen receptor. Cell 1986;46:1083–90.PubMedCrossRefGoogle Scholar
  34. 34.
    Ghayur T, Seemeyer TA, Kongshavn PAL, Gartner JG, Lapp WS. Graft-versus-host reactions in the beige mouse: An investigation of the role of host and donor natural killer cells in the pathogenesis of graft-versus-host disease. Transplantation 1987;44: 261–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Symington FW, Storb R. Mechanisms of tissue damage in human acute graft-versus-host disease. J Immunol Immunopharmacol 1989;9:214–9.Google Scholar
  36. 36.
    Piguet PF. Tumor necrosis factor and graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Verrara J, Atkinson K (eds). Graft-vs-host disease: Immunology, pathophysiology and treatment. Marcel Dekker, New York 1990:225–76.Google Scholar
  37. 37.
    Ferrara JL, Guillen FJ, van Dijken PJ, Marion A, Murphy GF, Burakoff SJ. Evidence that large granular lymphocytes of donor origin mediate acute graft-versus-host disease. Transplantation 1989;47:50–4.PubMedCrossRefGoogle Scholar
  38. 38.
    Rappeport J, Mihm M, Reinherz E, Lopansri S, Parkman R. Acute graft-versus-host disease in recipients of bone-marrow transplantation from identical twin donors. Lancet 1979;ii:7 17-20.Google Scholar
  39. 39.
    Hess AD, Horwitz L, Beschorner WE, Santos GW. Development of graft-versus-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development ofcytotoxic Tlymphocytes with apparent polyclonal anti-la specificity, including autoreactivity. J Exp Med 1985; 161:718–30.PubMedCrossRefGoogle Scholar
  40. 40.
    Maraninchi D, Blaise, Rio B, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987;i: 175–8.CrossRefGoogle Scholar
  41. 41.
    Mitsuyasu RT, Champlin RE, Gale RP, et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. Ann Intern Med 1986;105:20–6.PubMedGoogle Scholar
  42. 42.
    Waldmann H, Hale G, Cividalli G, et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984;i:483–5.CrossRefGoogle Scholar
  43. 43.
    Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation of severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983;61:341–8.PubMedGoogle Scholar
  44. 44.
    Schattenberg A, de Witte T, Preijers F, et al. Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation. Blood 1990;75:1356–63.PubMedGoogle Scholar
  45. 45.
    Filipovich AH, Vallera D, McGlave P, et al. T-cells depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation: The correlation between residual CD5 negative T-cells and subsequent graft-versus-host disease. Transplantation 1990;9:401–15.Google Scholar
  46. 46.
    Jansen J, Hanks S, English D, Karaffa R, Akard L. Immunomagnetic depletion of CD8+ lymphocytes from marrow grafts. In: Worthington-Write DA, Gee A, Gross S (eds). Advances in bone marrow purging and processing. Wiley-Liss, Inc, New York; 405–10.Google Scholar
  47. 47.
    Butturini A, Gale RP. T-cells depletion in bone marrow transplantation for leukemia: Current results and future directions. Bone Marrow Transpl 1988;3:185–92.Google Scholar
  48. 48.
    Sirchia G, Parravicini A, Rebulla P, Fattori L, Milani S. Evaluation of three procedures for the preparation of leukocyte-poor and leukocyte-free red blood cells for transfusion. Vox Sang 1980;38:197–204.PubMedCrossRefGoogle Scholar
  49. 49.
    Lane TA, Anderson KC, Goodnough LT, et al. Leukocyte reduction in blood component therapy. Ann Intern Med 1992;117:151–62.PubMedGoogle Scholar
  50. 50.
    Korngold R, Sprent J. T-cells subsets and graft-versus-host disease. An overview. Transplantation 1987;44:335–9.CrossRefGoogle Scholar
  51. 51.
    Gratama JW, Naipal A, Oljan, et al. T-lymphocyte repopulation and differentiation after bone marrow transplantation. II. Early shifts in the ratio between T4+ and T8+ T-lymphocytes correlated with the occurrence of acute graft-versus-host disease. Blood 1984;63:1416–23.PubMedGoogle Scholar
  52. 52.
    Gratama JW, de Groot-Swings G, Slats J, Zwaan FE, Jansen J. Correlation between the fraction size of the peripheral blood T8 T-lymphocyte subset of marrow donors and the development of acute graft-versus-host disease. Exp Hematol 1984;12:51–2.Google Scholar
  53. 53.
    Champlin R, Ho W, Gajewski J, et al. Selective depletion of CD8+ lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990;76:418–23.PubMedGoogle Scholar
  54. 54.
    Champlin R, Jansen J, Ho W, et al. Retention of graft-versus-leukemia using selective depletion of CD8-positive Tlymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia. Transplant Proc 1991;23:1695–6.PubMedGoogle Scholar
  55. 55.
    Sprent J, Anderson RE, Miller JF. Radiosensitivity of T and B lymphocytes. II. Effect of irradiation on response of T-cells to alloantigens. Eur J Immunol 1974;4: 204–10.PubMedCrossRefGoogle Scholar
  56. 56.
    Valerius NH, Johansen KS, Nielson OS, Platz P, Rosenkvist J, Sørenson H. Effect of in vitro x-irradiation on lymphocyte and granulocyte function. Scand J Haematol 1981;27:9–18.PubMedCrossRefGoogle Scholar
  57. 57.
    Rosen NR, Weidner JG, Boldt HD, Rosen DS. Prevention of transfusion associated graft-versus-host disease. Selection of adequate dose of gamma radiation. Transfusion 1993;33:125–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Zwaan FE. Haemopoietic cells in human peripheral blood. (Thesis). J.H. Pasman,’ s-Gravenhage 1980.Google Scholar
  59. 59.
    Deeg HJ, Bazar L, Sigaroudinia M, Cottler-Fox M. Ultraviolet B light inactivates bone marrow Tlymphocytes but spares hematopoietic precursor cells. Blood 1989; 73:369–71.PubMedGoogle Scholar
  60. 60.
    Cohn ML, Cahill RA, Deeg HJ. Hematopoietic reconstitution and prevention of graft-versus-host disease with UVB-irradiated haploidentical murine spleen and marrow cells. Blood 1991;78:3317–22.PubMedGoogle Scholar
  61. 61.
    Deeg HJ, Graham TC, Gerhard-Miller L, Appelbaum FR, Schuening F, Storb R. Prevention of transfusion-induced graft-versus-host disease in dogs by ultraviolet irradiation. Blood 1989;74:2592–5.PubMedGoogle Scholar
  62. 62.
    Kahan BD, Cyclosporine. N Eng J Med 1989;321:1725–38.CrossRefGoogle Scholar
  63. 63.
    Atkinson K, Biggs JC, Hayes J, et al. Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: Three distinct syndromes. Brit J Haematol 1983;54:59–67.CrossRefGoogle Scholar
  64. 64.
    Leitner C, Sinzinger H, Pohanka E, Schwarz M, Kretschmer G, Syré. Occurrence of hemolytic uremic syndrome under cyclosporine treatment: Accident or possible side effect mediated by a lack of prostacyclin-stimulating plasma factor. Transplant Proc 1983;15(suppl 1):571–3.Google Scholar
  65. 65.
    Markus PM, Cai X, Ming W, Demetris AJ, Fung JJ, Starzl TE. FK506 reverses acute graft-versus-host disease after allogeneic bone marrow transplant in rats. Surgery 1991;8:357–64.Google Scholar
  66. 66.
    Markus PT, Cai X, Ming W, Demetris AJ, Fung JJ, Starzl TE. Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation 1991;52:590–4.PubMedCrossRefGoogle Scholar
  67. 67.
    Fung JJ, Slessiani M, Abu-Elmagd K, et al. Adverse effects associated with the use of FK506. Transplant Proc 1991;15:3105–8.Google Scholar
  68. 68.
    Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989; 73:1729–34.PubMedGoogle Scholar
  69. 69.
    Atkinson K, Matias C, Guifere A, et al. In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4 alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood 1991;77:1376–82.PubMedGoogle Scholar
  70. 70.
    McCarthy PL, Abhyankar S, Neben S, et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991;78:1915–8.PubMedGoogle Scholar
  71. 71.
    Hervé P, Wijdenes J, Bergerat JP, et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 1990;75:1017–23.PubMedGoogle Scholar
  72. 72.
    Fahr A, Langer R, Ziegoleit S. Influence of pentoxifylline administered in vivo on synthesis of prostacyclin in human varicos veins. Biomed Bioclin ACTA 1988; 14: 29–36.Google Scholar
  73. 73.
    Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990;172:391–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Bianco JA, Appelbaum FR, Nemunaitis J, et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991;78:1205–11.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1993

Authors and Affiliations

  • J. Jansen
  • Q. Chang
  • L. P. Akard

There are no affiliations available

Personalised recommendations